Abstract 121P
Background
Colorectal cancer (CRC) is one of the most common malignancies, which has high morbidity and mortality rates globally. Recent studies have shown that tumor immune microenvironment (TIME) plays an important role in the development of CRC. Regulatory T cells (Tregs), a group of immunosuppressive cells, is significant in TIME. However, the role of Tregs in CRC is still controversial.
Methods
We used single-cell RNA sequencing (scRNA-seq) to profile the immune landscape of CRC, aiming to identify key subtype of Treg in the TIME that contribute to the development of CRC. The role of this key subtype of Treg in CRC prognosis was investigated by survival analyses of data from The Cancer Genome Atlas (TCGA) and multiple immunohistochemistry (mIHC) data of colorectal tumor samples collected from Zhongshan Hospital of Fudan University.
Results
Through scRNA-seq of tumor lesions of 13 patients with CRC, we found a new subtype of Treg, which was presented with high expression of baculoviral IAP repeat containing 3 (BIRC3). We confirmed its existence in colorectal cancer lesions by mIHC. Survival analysis of mIHC data from Zhongshan Hospital showed that Treg with high expression of BIRC3 was related with worse overall survival (OS) in CRC patients (P = 0.015). Survival analysis of TCGA database also reached a consistent result (P = 0.024). Multivariate analyses of both mIHC and TCGA data suggested that high expression of BIRC3 in Treg cells was an independent influencing factor for OS of CRC.
Conclusions
This study reveals that BIRC3 is expressed by Treg cells. High expression of BIRC3 in Treg cells indicates negative prognosis in CRC patients, which may provide a rationale for subsequent drug development and CRC management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract